| Name |
Yoshihiro Takemoto, Ph.D.
|
| Title |
Professor, School of Biomedical Science |
| Mail address |
takemoto@cim.tmd.ac.jp |
| Room number |
9F, Bldg. No.3, Tokyo Medical and Dental University |
|
| Academic title |
Ph.D., Biochemistry
Research Institute for Microbial Diseases,
Osaka University |
| Mail address |
takemoto@cim.tmd.ac.jp |
| Research etc. |
1. Basic Research:
Researcher, RIKEN.
Researcher, Glaxo Research Institute.
(Main Achievements: several journal articles in EMBO J., JBC, J. Immunology, Oncogene etc.; International patents in Lck, IKK kinase.)
2. Translational research:
Executive director, BIO venture company
President, BIO venture company
(Main experiences: Initial Public Offering (IPO), Management before and after IPO, Management Buyout, Management of Start-up company)
3. Clinical research:
Project Manager, International clinical manager at GlaxosmithKline (GSK).
(Main Achievements: Scientific journal publication; Global development, application, and approval of orphan and blockbuster products in the field of Respiratory, Diabetes, Critical care etc.)
4. Others:
Research Evaluation Committee for the Governmental Academia-Industry-Government Collaboration Project (MEXT: Ministry of Education, Culture, Sports, Science and Technology)
- Knowledge Cluster Evaluation Committee (2007)
- City Area Program Evaluation Committee (2008)
- City Area Program Evaluation Committee (2009)
- Knowledge Cluster Evaluation Committee (2009)
- Hokkaido Knowledge Cluster Bio-S Evaluation Committee (2007-)
the Governmental Think-Tank Committee, Hospital-Clinical Research Ethics Committee, Clinical Research Protocol Review Committee, advisor for numerous bio-ventures and major international company, management of venture company etc.
|
| Academic Society |
- The Molecular Biology Society of Japan
- The Japanese Society for Immunology
- Chem-Bio Informatics Society
- Japan Association for Omics-based Medicine (councilor) |
| Present theme |
Clinical research, Translational research, OMICS-research, Commercialization of OMICS technologies, Education for graduate student, Improving educational system, Matching, Management, Seed seeking
Global Linkage
Gloabal Linkage-Academia
China Medical Univ., Denmark DTU, Dundee Univ., Ecole normale superieure de Lyon, Fudan Univ., Glasgow Univ., Heidelberg Univ., Karolinska institutet, Leeds Univ., MD Anderson Cancer Center, Peking Union Medical College, Stanford Univ., USP, Wistar Institute etc.
Gloabal Linkage-Public
Copenhagen Capacity, Germany Biocluster BioRN, Japan America Society of Greater Philadelphia, JETRO Berlin, Sweden VINNOVA, UK Regional Development Agency, Scottish Development International, Several Embassies in Japan etc.
Gloabal Linkage-Industry
Japanese companies:Astellas Pharma, Esai Co. Ltd., Daiichi Sankyo Co. Ltd., AMR, GSK Japan etc
Others:Denmark BiosysADenmark CPH DesignADenmark Moller-Jensen Design, Denmark Santaris Pharma, Germany ApogenixAGermany BiocomAPhiladelphia - Science CenterAUK CXR BiosciencesAUK GSK etc.
. |
| Lectures |
- OMICS-based Drug Discovery and Development I & II
- Special lectures on Global Linkage between Academia and Industry
- Practice: Global Linkage Internship
- Practice: Basic Negotiation/ Debate
- Practice: Self Presentation |
| Main research papers etc. |
1. Clinical Research
- Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics., Respiratory Medicine., 101, 2488, 2007
- Several Clinical Research Protocols
2. Basic Research
- Synergism between the Calmodulin-binding and Autoinhibitory domains on Calcineurin Is essential for the Induction of their phosphatase activity., J. Biol. Chem., 275, 11728, 2000
- HS1 Interacts with Lyn and Is critical for erythropoietin-induced differentiation of erythroid cells., J. Biol. Chem., 275, 7887, 2000
- Growth Factor Receptor-Bound Protein 2 (Grb2) Association with Hemopoietic Specific Protein 1: linkage between Lck and Grb2., J. Immunol., 161, 625, 1998
- Aberrant TCR-mediated signaling in CD45-null thymocytes involved dysfunctional regulation of Lck, Fyn, TCR-zeta and ZAP-70., J. Immunol., 158, 5773, 1997
- LckBP1, a proline-rich protein expressed in hematopoietic lineage cells, directly associates with the SH3 domain of protein tyrosine kinase p56lck"., EMBO J., 14, 3403, 1995
- Cell type-specific trans-activation by the B-myb gene product: requirement of the putative cofactor binding to the C-terminal conserved domain., Oncogene, 10, 1699, 1995
- Multiple nuclear localization signals of the B-myb gene product., FEBS Letters, 350., 55, 1994
- Functional domain of the human B-myb gene product., J. Biol.Chem., 268, 14161, 1993
-@The promoter of the endoA cytokeratin gene is activated by a 3'downstream enhancer., NAR., 19, 2761, 1991
3. Review paper etc.
- Signal transduction of Lck and the Lck association proteins,Immunology 96-97, 33, 24-31 (1996)
- Oncogene myb, Tanpakushitsu-Kakusan-Koso, 37, 1555 (1992)
- Biologics, Japan Bioindustry Association research paper, Chapter 3, 86-95 (2007)
-Critical path in the pharmaceutical industry, CBI: Methods & Solution for Drug Discovery, 13-15 (2006)
-Biomarker in the pharmaceutical industry, Japan Bioindustry Association research paper, Chapter 3 Cutting edge technology, Biomedical area. 28-33 (2006)
4. Patents
1. Lck binding protein, United States Patent 5891673, 1999
2. A protein kinase (IKK4) involved in the phosphorrylation of IKB, 2000@(WO/2001/044444)
3. IKK3 kinase, 2003, United States Patent 6576439, 2003
|
|
|
|
|
